Patents Assigned to Cyclacel Limited
-
Publication number: 20090306098Abstract: A first aspect of the invention relates to a combination comprising roscovitine, or a pharmaceutically acceptable salt thereof, and a HDAC inhibitor selected from sodium butyrate, or a prodrug thereof, suberoylanilide hydroxamic acid (SAHA), sodium valproate and trichostatin A (TSA). A second aspect of the invention relates to a pharmaceutical product comprising roscovitine, or a pharmaceutically acceptable salt thereof, and a HDAC inhibitor selected from sodium butyrate, or a prodrug thereof, suberoylanilide hydroxamic acid (SAHA), sodium valproate and trichostatin A (TSA) as a combined preparation for simultaneous, sequential or separate use in therapy.Type: ApplicationFiled: November 13, 2006Publication date: December 10, 2009Applicant: Cyclacel LimitedInventors: Simon Green, Sheelagh Frame, Ian Fleming
-
Publication number: 20090274773Abstract: A first aspect of the invention relates to a combination comprising 2?-cyano-2?-deoxy-N4-palmitoyl-1-beta-D-arabi-nofuranosyl-cytosine, or a metabolite thereof, or a pharmaceutically acceptable salt thereof, and a cytotoxic agent selected from (a) a vinca alkaloid; (b) a taxane; (c) a cytosine analogue; (d) an anthracycline; and (e) a platinum antineoplastic agent. A second aspect of the invention relates to a pharmaceutical product comprising the above combination as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method for treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering the above combination.Type: ApplicationFiled: November 13, 2006Publication date: November 5, 2009Applicant: Cyclacel LimitedInventors: Simon Green, Ian Fleming, Eric Raymond
-
Patent number: 7612079Abstract: The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof wherein R2 is 2-hydroxymethylpyrrolidin-1-yl, or NHCH(R4)CH(R3)OH, wherein R3 is hydrogen or methyl and R4 is methyl, ethyl or isopropyl; R6 is 3-nitrophenylamino, 3,4-dimethoxybenzylamino, 3-iodobenzyl-amino, pyrid-2-yl-methylamino, pyrid-4-yl-methylamino or indan-5-amino; R9 is isopropyl or cyclopentanyl. In a further aspect, the invention relates to pharmaceutical compositions comprising said compounds, and the use thereof in treating antiproliferative disorders and or viral disorders.Type: GrantFiled: December 18, 2003Date of Patent: November 3, 2009Assignees: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin Fischer, Mike Jarman, Ted McDonald, Bernard Nutley, Florence Raynaud, Stuart Wilson, Paul Workman
-
Publication number: 20090270427Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.Type: ApplicationFiled: April 30, 2009Publication date: October 29, 2009Applicants: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin FISHER, Michael JARMAN, Edward MCDONALD, Bernard NUTLEY, Florence RAYNAUD, Stuart WILSON, Paul WORKMAN
-
Patent number: 7582642Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.Type: GrantFiled: January 11, 2005Date of Patent: September 1, 2009Assignees: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin Fischer, Michael Jarman, Edward McDonald, Bernard Nutley, Florence Raynaud, Stuart Wilson, Paul Workman
-
Publication number: 20090215805Abstract: The present invention relates to compounds of formula (I) or formula (II), or pharmaceutically acceptable salts thereof. Further aspects relate to pharmaceutical compositions comprising compounds according to the invention, and the use of said compounds in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.Type: ApplicationFiled: October 9, 2006Publication date: August 27, 2009Applicant: Cyclacel LimitedInventors: Gavin Wood, Christopher Meades, Peter Martin Fischer, Shudong Wang, Kenneth Duncan, Daniella I. Zheleva, Campbell Mcinnes, Mark Thomas
-
Patent number: 7576091Abstract: A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: X is S, O, or NH; “a” is a single bond; or “a” is a double bond and one of R3 and R4, and one of R5 and R6 are absent; R1 is H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, SO2-alkyl, CO2R13 and an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from R8 and R9; R2 is H, R8, or an alkyl group optionally substituted with one or more R8 groups; R3, R4, R5, and R6 are each independently selected from H, R8, an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more R8 groups; or R3 and R4, and/or R5 and R6 together represent ?O; R7 is H, R8, NH(CH2)nR9, CO(CH2)nR9, NHCO(CH2)nR9, O(CH2)nR9, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from R8 and R9; R8 is OR10, NR10R11, haType: GrantFiled: January 6, 2006Date of Patent: August 18, 2009Assignee: Cyclacel LimitedInventors: Campbell McInnes, Mark Peter Thomas, Shudong Wang, Neil McIntyre, Nicholas Westwood, Peter Martin Fischer
-
Patent number: 7544689Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or un branched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.Type: GrantFiled: September 28, 2005Date of Patent: June 9, 2009Assignees: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin Fischer, Michael Jarman, Edward McDonald, Bernard Nutley, Florence Raynaud, Stuart Wilson, Paul Workman
-
Publication number: 20090118315Abstract: A first aspect of the invention relates to a method of treating leukaemia or myelodysplastic syndromes (MDS), said method comprising administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, to a subject in accordance with a dosing regimen comprising at least one treatment cycle, wherein said treatment cycle comprises administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 7 consecutive days every 21 days or 14 consecutive days every 21 days.Type: ApplicationFiled: November 5, 2008Publication date: May 7, 2009Applicant: Cyclacel LimitedInventors: Athos Gianella-Borradori, Judy Chiao
-
Publication number: 20090074856Abstract: The present invention relates to a pharmaceutical formulation which comprises (i) a capsule, and (ii) a core comprising crystalline 2?-cyano-2?-deoxy-N4-palmitoyl-1-?-D-arabinofuranosylcytosine and a liquid carrier.Type: ApplicationFiled: December 22, 2006Publication date: March 19, 2009Applicant: Cyclacel LimitedInventors: Robert Westwood, Alastair Selkirk
-
Publication number: 20080318954Abstract: The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1: 1 is N or CH; Z2 and Z3 are each independently N or CR7; R1, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14(CH2)aCOOR15, (CH2)bCONR16R17, (CH2)cCOR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when R1 and R2 are both H, Z1 is CH; or Z2 is N; or Z1 is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine.Type: ApplicationFiled: February 7, 2005Publication date: December 25, 2008Applicant: Cyclacel LimitedInventors: Kenneth Duncan, Darren Gibson, Shudong Wang, Daniella I. Zheleva, Peter Martin Fischer
-
Publication number: 20080287439Abstract: The present invention relates to substituted pyrimidines of formula I, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders and/or viral disorders.Type: ApplicationFiled: July 29, 2008Publication date: November 20, 2008Applicant: Cyclacel LimitedInventors: Shudong Wang, Christopher Meades, Gavin Wood, Janice O'Boyle, Campbell McInnes, Peter Martin Fischer
-
Patent number: 7449544Abstract: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.Type: GrantFiled: May 19, 2003Date of Patent: November 11, 2008Assignee: Cyclacel LimitedInventors: Daniella I. Zheleva, Peter Martin Fischer, Campbell McInnes, Martin J. I. Andrews, Weng C. Chan, Gail E. Atkinson
-
Publication number: 20080249025Abstract: p21WAF1 interacts with cyclin D1 and Cdk4. Peptide fragments of p21 inhibit the interaction and/or affect Cdk4 activity. The peptides, derivative peptides and non-peptidyl mimetics thereof are useful in affecting activity of Cdk4, such as RB phosphorylation and cellular proliferation, indicative of therapeutic usefullness in treatment of tumors and other hyperproliferative disorders. Assay and screening methods allow identification of such modulators, especially inhibitors, of Cdk4 activity.Type: ApplicationFiled: June 4, 2008Publication date: October 9, 2008Applicant: Cyclacel LimitedInventors: Kathryn Lindsay Ball, David PHilip Lane
-
Patent number: 7427627Abstract: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.Type: GrantFiled: May 11, 2006Date of Patent: September 23, 2008Assignee: Cyclacel LimitedInventors: Shudong Wang, Christopher Meades, Andrew Osnowski, Gavin Wood, Peter Martin Fischer
-
Patent number: 7388015Abstract: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.Type: GrantFiled: March 26, 2004Date of Patent: June 17, 2008Assignee: Cyclacel LimitedInventors: Shudong Wang, Christopher Meades, Andrew Osnowski, Gavin Wood, Peter Martin Fischer
-
Publication number: 20080132484Abstract: The present invention relates to a homology model for PLK, and the use thereof in assays for the identification of small molecule PLK modulators. The invention further relates to PLK modulators identified by said assays, and their use in the treatment of PLK-related disorders such as proliferative disorders.Type: ApplicationFiled: November 12, 2004Publication date: June 5, 2008Applicant: CYCLACEL LIMITEDInventors: Campbell McInnes, Janice McLachlan, Mokdad Mezna, Peter Martin Fischer
-
Publication number: 20080125404Abstract: The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof is administered in an amount sufficient to down-regulate the levels of antinuclear antibodies. A further aspect of the invention relates to a combination comprising an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, such as SLE.Type: ApplicationFiled: August 25, 2005Publication date: May 29, 2008Applicant: Cyclacel LimitedInventors: Ariela Benigni, Carla Zoja, Giuseppe Remuzzi, Athos Gianella-Borradori
-
Patent number: 7312356Abstract: The present invention relates to 3?,28-diacetoxy-18-oxo-19,20,21,29,30-pentanorlupan-22-oic acid methanol solvate, its use in medicine and processes for its preparation.Type: GrantFiled: May 14, 2004Date of Patent: December 25, 2007Assignee: Cyclacel LimitedInventors: Peter Martin Fischer, Jan Sarek, Paul M. Blaney, Piers Collier, John R. Ferguson, Jonathan D. Hull
-
Patent number: 7262202Abstract: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.Type: GrantFiled: September 24, 2003Date of Patent: August 28, 2007Assignee: Cyclacel LimitedInventors: Peter Martin Fischer, Shudong Wang, Gavin Wood